A new asthma drug named Lunsekimig could be the answer for millions who remain dependent on inhalers. Here is what the phase ...
GoodRx reports that choosing the right asthma inhaler depends on symptom severity and frequency, with options for quick ...
The FDA has granted Fast Track designation to KT-621, a first-in-class oral STAT6 degrader for moderate to severe ...
Our expert pharmacist warns against mixing these medications with your morning cup of coffee.
KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ...
A new asthma drug, Lunsekimig, is showing promise in reducing inhaler dependence. Early trials report fewer symptoms, ...
Asthma patients can help their own health, and that of others, by taking part in clinical trials. There's no charge for ...
Orlando Health pulmonologist Dr. Sarah Cheyney outlines the signs, symptoms and available treatment options ...
Dupilumab was linked to improved lung function, asthma control, QOL, and biomarkers for up to 2 years in patients with uncontrolled severe asthma.
Kymera Therapeutics shares jump after FDA grants Fast Track to KT-621 for eosinophilic asthma, spotlighting its ...
The month of May is known as, National Asthma and Allergy Awareness Month, making it the ultimate time to prioritize ...
KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track de ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results